Which serotonin‑norepinephrine reuptake inhibitor (SNRI) should be started, at what dose, and what monitoring and contraindications are needed for a patient requiring this therapy?

SNRI Selection and Management

Start with duloxetine 30 mg once daily for one week, then increase to 60 mg once daily, as it has the best tolerability profile among SNRIs and does not require routine monitoring. 1

First-Line SNRI Choice

Duloxetine is the preferred SNRI for most clinical situations based on its superior safety profile compared to other agents in this class. The most common adverse effect is nausea, which is significantly reduced by starting at 30 mg once daily for 1 week before advancing to the therapeutic dose of 60 mg once daily 1.

Dosing Algorithm for Duloxetine

• Starting dose: 30 mg once daily
• Titration: Increase to 60 mg once daily after 1 week
• Maximum dose: 60 mg twice daily (120 mg/day) 1
• Trial duration: Allow 4 weeks to assess efficacy 1

Alternative SNRI: Venlafaxine

If duloxetine is not tolerated or contraindicated, venlafaxine is the second-line option, though it requires more cautious monitoring 1.

Dosing Algorithm for Venlafaxine

• Starting dose: 37.5 mg once or twice daily
• Titration: Increase by 75 mg each week as tolerated
• Target therapeutic dose: 150-225 mg/day
• Maximum dose: 225 mg/day 1
• Trial duration: 4-6 weeks (requires 2-4 weeks to reach efficacious dosing) 1

Critical Monitoring Requirements

For Duloxetine

• No routine monitoring required - aminotransferase monitoring is unnecessary 1
• Does not produce clinically important ECG or blood pressure changes 1
• Monitor for nausea (most common side effect)

For Venlafaxine

• Blood pressure monitoring is mandatory - dose-dependent increases can occur 1, 2
• ECG monitoring in patients with cardiac disease - cardiac conduction abnormalities reported in small numbers 1
• More frequent monitoring of cardiovascular parameters compared to duloxetine 3

Contraindications and Precautions

Duloxetine-Specific

• Creatinine clearance <30 mL/min - avoid use 4
• Hepatic impairment - avoid use; serious hepatotoxicity reported (unique to duloxetine, not a class effect) 4, 3

Venlafaxine-Specific

• Cardiac disease - prescribe with extreme caution due to conduction abnormalities 1
• Hypertension - use cautiously; monitor blood pressure closely 5, 2
• Higher cardiotoxicity in overdose compared to other SNRIs 3

Class-Wide Precautions

• Breast cancer patients on tamoxifen: Avoid SSRIs (they interfere with tamoxifen metabolism); SNRIs are safer 5
• Perioperative bleeding risk: SNRIs increase bleeding risk perioperatively 6
• Serotonin syndrome risk: Particularly when combined with other serotonergic agents 6

Discontinuation Protocol

Never abruptly stop SNRIs - both duloxetine and venlafaxine require dose tapering to prevent withdrawal syndrome 1. Venlafaxine has a particularly well-described withdrawal syndrome with adrenergic hyperactivity 1, 7.

Tapering Strategy

• Reduce dose gradually over several weeks
• Monitor for discontinuation symptoms (agitation, anxiety, dizziness, headache)
• Slower taper for patients on higher doses or longer treatment duration

Geriatric Considerations

In older adults, use lower starting doses and slower titration for both duloxetine and venlafaxine 1, 7. Duloxetine remains the preferred choice in this population due to fewer cardiovascular effects and no required monitoring 7.

Common Pitfalls to Avoid

• Starting duloxetine at 60 mg immediately - this increases nausea and discontinuation rates; always start at 30 mg 1
• Failing to monitor blood pressure with venlafaxine - this is non-negotiable given dose-dependent hypertension 1, 2
• Using venlafaxine in patients with cardiac disease without careful evaluation - conduction abnormalities are a real risk 1
• Prescribing duloxetine in renal or hepatic impairment - absolute contraindications 4
• Abrupt discontinuation - always taper to prevent withdrawal syndrome 1